Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant docetaxel + oxaliplatin + capecitabine versus oxaliplatin + capecitabine for stage IIIB-IIIC gastric or gastroesophageal junction adenocarcinoma
ChiCTR2000030887Phase 4Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jun 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of docetaxel, oxaliplatin and capecitabine in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Henan Cancer Hospital. Primary endpoint: Disease-free survival. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
docetaxeloxaliplatincapecitabine
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2000030887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030887.